Avoiding Harmful Palliative Chemotherapy Treatment in the End of Life: Development of a Brief Patient-Completed Questionnaire for Routine Assessment of Performance Status

Journal of Supportive Oncology

Volumn 10, Issue 6, 2012, Pages 230-237

  Näppä, Ulla ^a,b   Lindqvist, Olav ^a,c,d   Axelsson, Bertil ^a,b  

^a UMEÅ UNIVERSITY   (Sweden)

^b ÖSTERSUND HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Stockholms Sjukhem Foundation   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ANALYTICAL PARAMETERS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS RATING SCALE; EDMONTON SYMPTOM ASSESSMENT SYSTEM; EPITHELIUM TUMOR; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; PERFORMANCE STATUS IN PALLIATIVE CHEMOTHERAPY QUESTIONNAIRE; PREDICTION; PSYCHOMETRY; QUESTIONNAIRE; RATING SCALE; SENSITIVITY FOR CHANGE; TERMINAL CARE; TEST RETEST RELIABILITY; UROGENITAL TRACT CANCER; VALIDITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; PSYCHOMETRICS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF-ASSESSMENT; TERMINAL CARE;

EID: 84869131709     PISSN: 15446794     EISSN: 1879596X     Source Type: Journal    
DOI: 10.1016/j.suponc.2012.06.003     Document Type: Article

References (39)

1. Emanuel E.J., Young-Xu Y., Levinsky N.G., Gazelle G., Saynina O., Ash A.S. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med 2003, 138(8):639-643.
2. Murillo J.R., Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006, 11(10):1095-1099.
3. Näppä U., Lindqvist O., Rasmussen B.H., Axelsson B. Palliative chemotherapy during the last month of life. Ann Oncol 2011, 22(11):2375-2380.
4. McIllmurray M. The medical treatment of cancer in palliative care. Oxford Textbook of Palliative Medicine 2010, 513-525. Oxford University Press, New York. 4th ed. G. Hanks, N.I. Cherny, N.A. Christakis, M. Fallon, S. Kaasa, R. Portenoy (Eds.).
5. Maione P., Perrone F., Gallo C., et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005, 23(28):6865-6872.
6. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5(6):649-655.
7. Lilenbaum R., Wang X., Gu L., Kirshner J., Lerro K., Vokes E. Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small cell lung cancer and a performance status of 2: CALGB 30402. J Clin Oncol 2009, 27(27):4487-4491.
8. Liu S., Wang D., Chen B., Wang Y., Zhao W., Wu J. The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status. Lung Cancer 2011, 73(2):203-210.
9. Leong S.S., Toh C.K., Lim W.T., et al. A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly. J Thorac Oncol 2007, 2(3):230-236.
10. Baka S., Ashcroft L., Anderson H., et al. Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status ≤ 70) and advanced non-small cell lung cancer. J Clin Oncol 2005, 23(10):2136-2144.
11. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002, 346(2):92-98.
12. Martoni A.A., Tanneberger S., Mutri V. Cancer chemotherapy near the end of life: the time has come to set guidelines for its appropriate use. Tumori 2007, 93(5):417-422.
13. Pater J.L., Loeb M. Nonanatomic prognostic factors in carcinoma of the lung: a multivariate analysis. Cancer 1982, 50(2):326-331.
14. Keam B., Oh D.Y., Lee S.H., et al. Aggressiveness of cancer care near the end of life in Korea. Jpn J Clin Oncol 2008, 38(5):381-386.
15. Temel J.S., Greer J.A., Muzikansky A., et al. Early palliative care for patients with metastatic non-small cell lung cancer. N Engl J Med 2010, 363(8):733-742.
16. Joly F., Vardy J., Pintilie M., Tannock I.F. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol 2007, 18(12):1935-1942.
17. Stanley K.E. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980, 65(1):25-32.
18. Yates J.W., Chalmer B., McKegney F.P. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980, 45(8):2220-2224.
19. Balmer C.E., Thomas P., Osborne R.J. Who wants second-line, palliative chemotherapy?. Psychooncology 2001, 10(5):410-418.
20. Schnadig I.D., Fromme E.K., Loprinzi C.L., et al. Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer 2008, 113(8):2205-2214.
21. Hjermstad M.J., Fayers P.M., Bjordal K., Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: the QLQ-C30 (+ 3). J Clin Oncol 1998, 16(3):1188-1196.
22. Groenvold M., Petersen M.A., Aaronson N.K., et al. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006, 42(1):55-64. EORTC quality of life group.
23. Bruera E., Kuehn N., Miller M.J., Selmser P., Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991, 7(2):6-9.
24. Chang V.T., Hwang S.S., Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000, 88(9):2164-2171.
25. Tishelman C., Lövgren M., Broberger E., Hamberg K., Sprangers M.A. Are the most distressing concerns of patients with inoperable lung cancer adequately assessed?. A mixed-methods analysis. J Clin Oncol 2010, 28(11):1942-1949.
26. Smith T.J., Dow L.A., Virago E.A., Khatcheressian J., Matsuyama R., Lyckholm L.J. A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol 2011, 9(2):79-86.
27. Axelsson B., Sjödén P.O. Assessment of quality of life in palliative care: psychometric properties of a short questionnaire. Acta Oncol 1999, 38(2):229-237.
28. Henoch I., Axelsson B., Bergman B. The Assessment of Quality of life at the End of Life (AQEL) questionnaire: a brief but comprehensive instrument for use in patients with cancer in palliative care. Qual Life Res 2010, 19(5):739-750.
29. Streiner D.L., Norman G.R. Health Measurement Scales: A Practical Guide to Their Development and Use 2008, Oxford University Press, Oxford, England. 4th ed.
30. Lundström S., Fürst C., Friedrichsen M., Strang P. The existential impact of starting corticosteroid treatment as symptom control in advanced metastatic cancer. Palliat Med 2009, 23(2):165-170.
31. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates Inc, Hillsdale, NJ. 2nd ed.
32. Heedman P.A., Strang P. Symptom assessment in advanced palliative home care for cancer patients using the ESAS: clinical aspects. Anticancer Res 2001, 21(6A):4077-4082.
33. Matsuyama R., Reddy S., Smith T.J. Why do patients choose chemotherapy near the end of life?. A review of the perspective of those facing death from cancer. J Clin Oncol 2006, 24(21):3490-3496.
34. Cattell E., Arance A., Middleton M. Assessing outcomes in palliative chemotherapy. Expert Opin Pharmacother 2002, 3(6):693-700.
35. Quinten C., Coens C., Mauer M., et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009, 10(9):865-871. EORTC Clinical Groups.
36. Ferrans C.E. Differences in what quality-of-life instruments measure. J Natl Cancer Inst Monogr 2007, 2007(37):22-26.
37. Hashimoto K., Yonemori K., Katsumata N., et al. Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist 2009, 14(7):752-759.
38. Yun Y.H., Kwak M., Park S.M., et al. Chemotherapy use and associated factors among cancer patients near the end of life. Oncology 2007, 72(3-4):164-171.
39. Kao S., Shafiq J., Vardy J., Adams D. Use of chemotherapy at end of life in oncology patients. Ann Oncol 2009, 20(9):1555-1559.